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ABSTRACT  
Objective: This study evaluates the hypoglycemic effect of COQ10 and Vitamin E are determined using STZ induced diabetic rats.  
Methods: Rats selected for this study were divided into five groups of ten rats each as follows: first group Normal control rats, the second is 
considered as diabetic groups, injected intraperitoneal with a single dose of STZ (60 mg/kg B. wt). the third group Diabetic rats orally administered 
glibenclamide drug 10 mg/kg B. wt daily for 30 d 4th. And 5th groups were treated orally glibenclamide combined with vitamin E (2% concentration 
added to the normal basal diet), or coenzyme Q10 at the dose of 10 mg/kg i. p. daily for 30 consecutive days in addition histological examinations of 
liver, kidney and brain were carried out to confirm the biochemical changes of the diabetic group of rats. 
Results: All liver enzymes activities alanine and aspartate transferases and alkaline phosphatase (AST, ALT and ALP respectively), kidney function 
tests; creatinine and total urea, inflammatory biomarkers; CRP, IL-10 and TNF-α. Neurotransmitters; acetylcholine and acetylcholine esterase were 
enhanced with the highest degree in groups treated with COQ10 or vitamin E in addition to glibenclamide dug, almost restore the normal 
histological architecture of liver, kidney and brain. 
Conclusion: Orally supplemented glibenclamide with coenzyme Q10 or vitamin E showing significantly reduced blood glucose levels in STZ induced 
diabetic rats. It also showed hypolipidemia as well as hepatoprotective effects, enhance histological feature of liver, kidney and brain.  
Keywords: Hyperglycemia; Coenzyme Q10; Vitamin E; STZ; Liver, Kidney; Brain. 
 
INTRODUCTION 
Increased oxidative stress has been implicated in the etiology 
(especially type 1) and pathology (both type 1 and type 2 of diabetic 
complications [1]. In diabetes, hyperglycemia increased production 
of reactive oxygen and nitrogen species (ROS and RNS), increased 
protein glycation, increased lipolysis, ketogenesis and decreased 
antioxidants, glutathione (GSH) and NADPH have all been reported 
to be involved [2]Pancreatic beta cells exposed to hyperglycemia 
and reactive oxygen species displayed reduced insulin secretion and 
increased insulin resistance [3]. It has been proposed that during the 
early stages of beta cell destruction, hyperglycemia–induced 
mitochondrial over work and alterations in the rate of oxygen 
utilization by respiratory chain complexes are possible mechanisms 
for development of diabetes-related complications. It is therefore 
suggested that suppression of oxidative stress in beta cells may 
prevent or delay the onset of type 1 and progression of type 2 
diabetes and related complications. Several studies have also shown 
that treatment with antioxidants protects against the onset of 
diabetes [4]. 
It has been reported that diabetic rats display higher O2 
consumption and reduced mitochondrial antioxidant GSH and 
coenzyme Q pools than non-diabetic rats [5]. Consequently 
prevention of mitochondrial oxidative damage and ROS production 
may have therapeutic potential. It is known that diabetic 
complications and increased oxidative stress are tissue specific and 
are accompanied by altered glucose transport, mitochondrial oxygen 
metabolism and energy production [5]. 
Coenzyme Q10 is an endogenous antioxidant that scavenges free 
radicals directly, inhibits bimolecular oxidation and affects 
antioxidants in vivo [6]. Coenzyme Q10 treatment effect on 
antioxidant pathways in normal and Streptozotocin--induced 
diabetic rats [7]. In this light, the objective of the current 
investigation was to study the beneficial effects of coenzyme Q10 in 
Streptozotocin-induced diabetic rats. 
Several antioxidant enzymatic and non-enzymatic systems in the cell 
inactivate free radicals to reduce the damage caused by them. These 
antioxidants include glutathione, enzymatic systems, and vitamins A, 
C, and E. The effect of vitamin E on free radicals is mainly important 
for preventing or delaying many degenerative diseases, such as 
cancer, cardiovascular inflammatory diseases, cellular alterations 
attributable to the aging process, and neurological diseases [8]. 
Vitamin E promoted a reduction in the indicators of oxidative stress 
and protein glycation in diabetic patients. Treatment of vitamin E 
show a reduction in lipid peroxidation, an increase in superoxide 
dismutase activity, an increase in nervous system conductance 
velocity and protection against nervous system dysfunction [9]. The 
goal of the present study is to determine whether vitamin E (α-
tocopherol) or coenzyme Q10 separately co-administered with 
glibenclamide more effective and have any influence on different 
metabolic disorders in diabetic rats.  
MATERIALS AND METHODS 
Chemicals 
All kits are the products of Bio systems (Alcobendas, Madrid, Spain), 
Sigma Chemical Company (St. Louis, MO, USA) and Bio diagnostic 
Company (Cairo, Egypt). All other chemicals in the present study are 
of analytical grade, products of Sigma, Merck and Aldrich. 
Experimental animals 
Male Wister rats (200-220 g) were used for the evaluation of 
combined effects of glibenclamide+vitamin E or coenzyme Q10 or 
glibenclamide given alone. Rats were provided by the Animal House 
of the National Research Center (NRC) and housed in a temperature-
controlled environment (26-29 °C) with a fixed light/dark cycle for 
one week as an adaptation period to acclimatize under normal 
combination with free access to water and food. The present study is 
approved by the Ethical Committee of the National Research Center 
(NRC), Egypt, provided that the animals will not suffer at any stage 
of the experiment. 
Experimental design 
Rats selected for this study were divided into five groups of ten rats 
each as follows:  
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Group 1: Normal healthy control rats,  
Group 2: Is considered as diabetic groups; where type 2 diabetes was 
induced by STZ. Each rat was injected intraperitoneal with a single 
dose of STZ (60 mg/kg body weight dissolved in 0.01 M citrate buffer 
immediately before use [10]. After injection, animals had free access 
for food and water and were given 5% glucose solution to drink 
overnight to encounter hypoglycaemic shock. Animals were checked 
daily for the presence of glycosuria [11]. Animals were considered to 
be diabetic if glycosuria was present for 3 consecutive days. After 3 d 
of STZ injection fasting blood samples were obtained and fasting blood 
sugar was determined (>300 mg/dl). Hyperglycaemic rats were used 
for the experiment and classified as follows:  
Group 3: Diabetic rats orally administered antidiabetic glibenclamide 
reference drug 10 mg/kg body weight daily for 30 d [12].  
Groups 4 and 5: Diabetic rats orally supplemented glibenclamide 
with vitamin E (2% concentration added to the normal basal diet, 
[13], and coenzyme Q10 at the dose of 10 mg/kg i. p. [7]. daily for 30 
consecutive days, during the study standard food and water were 
provided ad libitum 
Sample preparations 
After 30 d of treatments, rats were fasted overnight (12-14 h), 
anesthetized by diethyl ether and blood collected by puncture of the 
sublingual vein in the clean and dry test tube, left 10 min to clot and 
centrifuged at 3000 rpm for serum separation. The separated serum 
was used for biochemical analysis of liver enzymes alanine and 
aspartate transferases and alkaline phosphatase (AST, ALT and ALP 
respectively), kidney function tests; creatinine and total urea, 
inflammatory biomarkers; CRP, IL-10 and TNF-α. 
Neurotransmitters; acetylcholine and acetylcholine esterase were 
also investigated. After blood collection, rats of each group were 
sacrificed, the liver, kidney and brain were removed immediately (a 
part was fixed in 10% formalin for histopathological examination.  
Serum biochemical examination 
Glucose was determined in serum by the method of Trinder [14], 
colorimetric assay method kits (Biodiagnostic Chemical Company, 
Cairo, Egypt).  
Lipid profile and kidney markers 
Triglycerides level was determined according to the method of 
Fassati and Prencipe [15], total cholesterol level was estimated 
according to the method of Allain et al.[16],while total lipid level was 
measured according to the method of Zollner and Kirsch[17]. 
(Biodiagnostic Chemical Company, Cairo, Egypt. 
Serum creatinine concentration was measured according to the 
method of Schirmeister [18] using colorimetric kit and total urea level 
was estimated according to the method of Fawcett and Scott [19] using 
colorimetric kit. Total urea and creatinine were carried out using 
diagnostic kits (Biodiagnostic Chemical Company, Cairo, Egypt). 
Inflammatory and brain cholinergic biomarkers  
Estimation of serum inflammatory markers; CRP, TNF-α, IL-10, brain 
cholinergic markers (acetyl cholinesterase and acetylcholine) was 
determined by ELISA; a sandwich enzyme immunoassay 
Liver injury biomarkers 
Aspartate and alanine aminotransferases (AST and ALT) enzyme 
activities were assayed according to the method of Reitman and 
Frankel [20]. ALP enzyme activity was determined according to the 
method described by Belfield and Goldberg [21]. Total protein was 
assayed in serum according to Bradford [22]. 
Oxidative stress markers and non-enzymatic-antioxidant enzyme 
Liver nitrite (NO) level was estimated according the method of 
Moshage et al.[23]. GSH level was assayed in liver homogenate 
according to the method of Beutler et al.[24]. Liver MDA level was 





Liver, Kidney and brain slices were fixed instantaneously in buffer 
neutral formalin (10%) for 24h for fixation then processed in 
automatic processors, embedded in paraffin wax (melting point 55-
60 °C) and paraffin blocks were obtained. Sections of 4 μm thicknes 
were prepared and stained with Haematoxylin and Eosin (H&E) 
stain [26]. The cytoplasm stained shades of pink and red and the 
nuclei gave blue colour. The slides were examined and 
photographed under a light microscope. 
Statistical analysis  
Data presented as mean±S. D, n=10. Statistical analysis was carried 
out by using one way analysis of variance (ANOVA) SPSS (version 
11) computer program and Co-state computer program, where 
unshared letter is significant at P ≤ 0.05. 
RESULTS  
Significant increase in blood glucose level, while the significant 
decrease in α-amylase enzyme activity ascertained the diabetic 
state with percentages 231.84 and 35% respectively. Marked 
amelioration in blood glucose level and α-amylase enzyme activity 
up on treatment of diabetic rats with glibenclamide with 
percentage of improvement 231.14%. While, the improvement 
percentages reached to 227.22 and 190.39%, respectively of 
glibenclamide co-administrated with vitamin E and coenzyme Q10 
respectively as revealed in table (1). 
Table 1: Blood glucose and α-amylase levels in STZ induced diabetic in addition of vitamin E or coenzymeQ10 with glibenclamide drug rats 
Groups Parameters Glucose (mg/dl)  α-amylase (U/l) 
Negative control mean±SD 95.72±4.66cd 1151.12±67.14a 
Diabetic rats mean±SD 





Diabetic rats treated with antidiabetic-glibenclamide drug mean±SD 
% Change  







Diabetic rats treated with Glibemclamide+Vitamin E  mean±SD 
% Change  







Diabetic rats treated with Glibemclamide+CoenzymeQ10 mean±SD 
% Change  







Data are means±SD of ten rats in each group. Statistical analysis was carried out using Costat computer program coupled with post-hoc least 
significance difference (LSD). Unshared letters indicate significant differences at P<0.05. 
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Liver function enzyme activities (AST, ALT and ALP), LDH and total 
protein content, significant increase in the enzyme activities; AST, 
ALT and ALP were detected in diabetic rats as compared to normal 
control (table 2). However, treatment of diabetic rats with 
glibenclamide antidiabetic drug alone or combined with vitamin E and 
coenzyme Q10 showed enhancement in liver enzyme activities with the 
highest percentages of amelioration for Glibenclamide co-administered 
with coenzyme Q10(47.03, 105.38 and 67.80 %, respectively for 
AST,ALT and ALP enzyme activities) as shown in table (2). 
Although, LDH enzyme activity (table 3) showed the significant 
decrease in diabetic rats (60.00 %) as compared to the normal one. 
While, total protein content is insignificantly changed in diabetic 
rats. Treatments, of diabetic rats with Glibenclamide alone or co-
administered with vitamin E and coenzyme Q10 showed 
improvement percentages in LDH enzyme activity reached to 49.65, 
40.00 and 39.24%, respectively. 
Lipid profile (table 4) showed, significant increase in diabetic rats 
with percentages increase recorded 100.56, 216.32 and 67.35 %, for 
TG, TC and TL respectively as compared to normal control rats. The 
oral supplementation of glibenclamide, glibenclamide given with 
vitamin E or with coenzyme Q10 to diabetic rats resulted in 
enhancement in lipid profile level with a marked percentages of 
amelioration upon co-administered Glibenclamide with coenzyme 
Q10(121.14, 113.35 and 102.94 %, respectively for TG,TC and TL). 
 
Table 2: Serum AST, ALT and ALP enzyme activities in STZ induced diabetic in addition of vitamin E or coenzymeQ10 with glibenclamide 
drug rats 






Negative control  mean±SD 2.36±0.08b 1.30±0.07bcd 79.86±6.59bc 
Diabetic rats mean±SD 







Diabetic rats treated with antidiabetic-glibenclamide drug mean±SD 
% Change to control 










Diabetic rats treated with glibenclamide+Vitamin E  mean±SD 
% Change to control 










Diabetic rats treated with glibenclamide+coenzymeQ10 mean±SD 
% Change to control 










Data are means±SD of ten rats in each group. Statistical analysis was carried out using Costat computer program coupled with post-hoc least 
significance difference (LSD). Unshared letters indicate significant differences at P<0.05. 
 
Table 3: Serum LDH enzyme activity and total protein content in STZ induced diabetic in addition of vitamin E or coenzymeQ10 with 
glibenclamide drug rats 
Groups Parameters LDH (U/l) Protein (TP) (mg/ml) 
Negative control mean±SD 26500±34.15a 89.55±4.94a 
Diabetic rats mean±SD 





Diabetic rats treated with antidiabetic-glibenclamide drug mean±SD 
% Change to control 







Diabetic rats treated with Glibemclamide+Vitamin E  mean±SD 
% Change to control 







Diabetic rats treated with glibemclamide+CoenzymeQ10 mean±SD 
% Change to control 







Data are means±SD of ten rats in each group. Statistical analysis was carried out using Costat computer program coupled with post-hoc least 
significance difference (LSD). Unshared letters indicate significant differences at P<0.05. 
 
Table 4: lipid profile TG, TC and TL in STZ induced diabetic in addition of vitamin E or coenzymeQ10 with glibenclamide drug rats 
Groups Parameters TG (mg/dl) TC (mg/dl) TL (mg/dl) 
Negative control mean±SD 88.90±14.69b 26.22±9.00f 365.00±25.03b 
Diabetic rats mean±SD 







Diabetic rats treated with ant diabetic-glibenclamide drug mean±SD 











Diabetic rats treated with Glibemclamide+Vitamin E  mean±SD 











Diabetic rats treated with glibemclamide+coenzymeQ10 mean±SD 











Data are means±SD of ten rats in each group. Statistical analysis was carried out using Costat computer program coupled with post-hoc least 
significance difference (LSD). Unshared letters indicate significant differences at P<0.05. 
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It is clear from table (5) that, diabetic rat’s recorded significant 
increase in NO and MDA levels by 83.66 and 52.50, % respectively as 
compared to normal control rats. While, significant reduction in GSH 
level (52.06%) was observed. Treatment of diabetic rats with 
glibenclamide alone or combined with vitamin E and coenzyme Q10 
demonstrated the highest percentages of improvement in NO, MDA 
and GSH levels with Glibenclamide co-administered with coenzyme 
Q10 (123.36, 48.09 and 75.00%, respectively for NO,GSH and MDA).
 
Table 5: Antioxidant scavenging activity in STZ induced diabetic in addition of vitamin E or coenzymeQ10 with glibenclamide drug rats 






Negative control mean±SD 19.77±1.93b 103.37±5.07ab 0.40±0.09b 
Diabetic rats mean±SD 







Diabetic rats treated with antidiabetic-glibenclamide drug mean±SD 
% Change  










Diabetic rats treated with glibenclamide+Vitamin E  mean±SD 
% Change to control 










Diabetic rats treated with glibenclamide+coenzymeQ10 mean±SD 
% Change to control 










Data are means±SD of ten rats in each group. Statistical analysis was carried out using Costat computer program coupled with post-hoc least 
significance difference (LSD). Unshared letters indicate significant differences at P<0.05. 
 
Table (6) declared, diabetic rats exhibited significant increase in CRP 
and TNF-α level by 162.60 and 76.15 %, respectively as compared to 
normal control rats. While, significant reduction in IL-10 level 
(46.23%) was observed. Treatment of diabetic rats with 
glibenclamide alone or combined with vitamin E and coenzyme Q10 
demonstrated the highest percentages of improvement in 
CRP,TNF—α and IL-10 levels with glibenclamide co-administered 
with coenzyme Q10(159.15, 54.55 and 34.35%, respectively for 
CRP,TNF-α and IL-10). 
Kidney function tests in table (7) showed significant increase in 
creatinine and total urea levels in diabetic rats with percentages 
increase reached to 80.00 and 20.42 % respectively as compared to 
diabetic rats. Treatment of diabetic rats with glibenclamide alone, 
glibenclamide+vitamin E and glibenclamide+coenzyme Q10 showed, 
the highest percentages of improvement in creatinine and total urea 
levels with glibenclamide co-administered either with vitamin E 
(92.00 and 55.63%, respectively) or coenzyme Q10(80.00 and 
57.40%, respectively). 
 
Table 6: The inflammatory biomarkers; CRP, TNF-α and IL-10 levels in STZ induced diabetic in addition of vitamin E or coenzymeQ10 with 
glibenclamide drug rats 
Groups Parameters CRP (pg/ml) TNF-α (ρg/ml) IL-10 (ρg/ml) 
Negative control mean±SD 5.19±1.22e 109.00±10.33e 66.60±6.03ab 








Diabetic rats treated with glibenclamide mean±SD 
% Change 










Diabetic rats treated with glibenclamide+Vitamin E mean±SD 
% Change 










Diabetic rats treated with Coenzyme Q10 mean±SD 
% Change 










Data are means±SD of ten rats in each group. Statistical analysis was carried out using Costat computer program coupled with post-hoc least 
significance difference (LSD). Unshared letters indicate significant differences at P<0.05. 
 
Table 7: kidney function tests (creatinine and total urea levels), in STZ induced diabetic in addition of vitamin E or coenzymeQ10 with 
glibenclamide drug rats 
Groups Parameters Creatinine (mg/dl) Urea (mg/dl) 
Negative control mean±SD 0.25±0.92b 99.13±8.50b 
Diabetic rats mean±SD 





Diabetic rats treated with glibenclamide mean±SD 
% Change to control 







Diabetic rats treated with glibenclamide+Vitamin E mean±SD 
% Change to control 







Diabetic rats treated with glibenclamide+Coenzyme Q10 mean±SD 
% Change to control 







Data are means±SD of ten rats in each group. Statistical analysis was carried out using Cost at computer program coupled with post-hoc least 
significance difference (LSD). Unshared letters indicate significant differences at P<0.05. 
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Table 8: Cholinergic neural Ach and AchE in STZ induced diabetic in addition of vitamin E or coenzymeQ10 with glibenclamide drug rats 
Groups Parameters Ach (μmol/mg protein) AchE (U/mg protein) 
Negative control mean±SD 89.00±7.42 598.90±20.14 
Diabetic rats mean±SD 





Diabetic rats treated with glibenclamide mean±SD 
% Change to control 







Diabetic rats treated with glibemclamide+Vitamin E mean±SD 
% Change to control 







Diabetic rats treated with Glibenclamide+Coenzyme Q10 mean±SD 
% Change to control 







Data are means±SD of ten rats in each group. Statistical analysis was carried out using Cost at computer program coupled with post-hoc least 
significance difference (LSD). Unshared letters indicate significant differences at P<0.05. 
 
Significant decrease in ACh level in diabetic rats, while significant 
increase in AChE with percentages reached to 32.58 and 48.81 %, as 
compared to normal control rats. Treatments of diabetic rats with 
Glibenclamide co-administered with either vitamin E or coenzyme 
Q10 exhibited the higher percentages of amelioration in Ach and Ach 
levels than glibenclamide alone (26.63, 49.09 %, respectively for 
Glibenclamide+vitamin E and 28.88, 46.63%, respectively for 
Glibenclamide+coenzyme Q10)(table 8). 
Histopathological examination  
Fig. (1) Control rat liver section showing normal hepatic chord, 
hepatocytes, central canal and Kupffer cells Photomicrograph of 5 
microns thick H & E stained paraffin section from the liver of a 
normal rat (A) showing normal lobular pattern with a 
centrilobular vein and radiating irregular anatomizing plates of 
hepatocytes with intervening sinusoids. In Diabetic group (B) 
showing hepatocellular degeneration, vacuolation of hepatocytes 
along with clumping of cytoplasm and necrosis (B*) The same 
section of liver section of diabetic rat showing The same section of 
Liver of diabetic rat revealed binuclear hepatocytes (→) and 
sinusoidal dilatations, H and E × 100. In the group treated with 
glibenclamide showing protection with mild degenerative changes 
(C). In group treated with COQ10 in addition to glibenclamide 
showing a significant enhancement in hepatic cells, proliferation of 
bile ductules (Arrow)(D). In group treated with vitamin E in 
addition to glibenclamide showing nearly normal (E). 
 
 
Fig. 1: Section of liver showing normal rat (A), Diabetic group 
(B) and (B*), group treated with glibenclamide (C), group 
treated with COQ10 in addition to glibenclamide (D), group 
treated with vitamin E in addition to glibenclamide (E) 
Fig. (2) Photomicrograph of control kidney section 200× showed 
normal Glomerulus, Bowman’s space and renal parenchyma (A). On 
the other side, the kidney sections of+ve control exhibited some 
hyperplastic glomeruli and swollen lining epithelium of the renal 
tubules (B) Other Photomicrograph of kidney tissue section of 
revealed proximal convoluted tubules show destructed epithelial 
lining 400x.(B*) Glibenclamide, revealed almost normal arranged of 
renal corpuscle with normal glomerulus stained with (H&E) 200x. 
(C) In group treated with COQ10 in addition to glibenclamide 
showing normal glomeruli (D). In group treated with vitamin E in 
addition to glibenclamide showing nearly normal histology (E). 
 
 
Fig. 2: Section of kidney showing normal rat (A), Diabetic group 
(B) and (B*), group treated with glibenclamide (C), group 
treated with COQ10 in addition to glibenclamide (D), group 
treated with vitamin E in addition to glibenclamide (E) 
 
Fig. (3) Histological examination of the brain (hippocampus) Control 
rat hippocampus section showing normal glial cell layer, molecular 
layer and Purkinje layer (A). Brain section of diabetic rat showing 
necrotic degeneration of Purkinje neurons, enlargement of 
perikaryon with vacuoles filled with colorless debris, lysis of glial 
cells and neuroplasm (B), (B*) The same section of brain section of 
diabetic rat With higher magnification 400x. Brain section 
glibenclamide treatment showing diminution of pathology with only 
mild necrotic and degenerative changes (C). In COQ10 treatment (D) 
and vitamin E treatment group the number of apoptotic neurons was 
reduced significantly compared to control group (E).  
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Fig. 3: Section of brain showing normal rat (A), Diabetic group 
(B) and (B*), group treated with glibenclamide (C), group 
treated with COQ10 in addition to glibenclamide (D), group 
treated with vitamin E in addition to glibenclamide (E) 
 
DISCUSSION 
Diabetes mellitus is a major disease associated with disturbances of 
in carbohydrate, fat and protein metabolism, affecting nearly 10 % 
of the population. STZ-induced hyperglycemia has been described as 
an utilizable experimental model to study the activity of 
hypoglycemic agents. This study was undertaken to evaluate that the 
aminotransferases (ALT and AST) and ALP levels were significantly 
increased in STZ-treated animals, the increase in aminotransferases 
levels may be due to the cellular damage in the liver which caused by 
STZ induction [27].  
Ali et al. [28] observed increased levels of serum ALP in pathological 
conditions involving the liver and kidney. Increase in the levels of 
ALP in diabetic rats was Cell damage has been implicated in a variety 
of chronic diseases. Oxidative stress and alterations in glucose 
metabolism are important risk factors for diabetes and its related 
complications. Advanced glycation end products (AGEs) and their 
carbonyl derivatives contribute to the pathogenesis of diabetes by 
their interaction with specific cell membrane receptors triggering to 
induce the expression of pro-inflammatory mediators and elicit 
oxidative stress, which exacerbate diabetic complications [29]. A 
significant elevation in liver function markers associated with 
insignificant change in total protein content as compared to the 
normal control group was illustrated (table 2). The high serum levels 
of these enzymes after STZ treatment are associated with 
inflammation and/or injury to liver cells, a condition known as 
hepatocellular liver injury and apoptosis. Supporting our findings, It 
has been found that hyperglycemia resulted in hepatolysis was 
reflected by increased blood serum aminotransferases as one of the 
consequences of diabetic complication. The increment of such serum 
markers may be due to the leakage of these enzymes from the liver 
cytosol into the blood stream as a result of hepatomegaly [27]. 
It was observed that, the levels of TG, TC and TL in diabetic rats were 
increased in a significant way. Insulin activates lipoprotein lipase 
which hydrolyzes triglycerides. Insulin deficiency results in the 
failure of activate lipase enzyme consequently, causing 
hypertriglyceridemia [30]. The present results run in parallel with 
the results achieved by Seth et al. [3] who demonstrated significant 
elevation in lipid profile in the serum of diabetic rats.  
The present results indicate significant elevation in NO and MDA levels 
in liver of diabetic rats (table 5). These elevated levels may be due to 
oxidative stress which is considered as one of the necessary causative 
factors that link diabetes with the pathogenic complications of several 
tissues [32]. Experimental studies suggested that NO may be 
responsible for the increased liver injury [33]. 
Lipid peroxidation can damage protein, lipid, carbohydrates, and 
nucleic acids and is one of the risk factors of protein glycation, 
elevated rates of liver lipid peroxidation accompanied with 
deterioration in glucose tolerance in GSH-depleted rats. It has been 
suggested that in free radical initiating systems, the deterioration in 
glucose tolerance is attributed to impaired insulin action [34]. 
DM is associated with the oxidative stress resulted from the 
increased production of free radicals with/or a marked reduction of 
antioxidant defenses [35]. The direct toxicity of NO is enhanced by 
its reacting with superoxide radical to give secondary toxic oxidizing 
species, such as peroxy Nitrite (ONOO) which is capable of oxidizing 
cellular structure and causes lipid peroxidation The present results 
clearly indicate elevated NO and MDA levels in diabetic rats [30]. 
Initiation of lipid peroxidation by free radicals, in the lipid moiety of 
the cell membrane, was supposed to result in distortion of the 
structural and functional integrity of the cell membrane or internal 
cellular components [36]. The current data show also that STZ 
caused a reduction in GSH in the liver of diabetic rats (table 5). This 
may be attributed to excess production of ROS and inhibition in free 
radical scavenging enzyme SOD. SOD neutralizes superoxide as it 
cannot cross the lipid membrane producing hydrogen peroxide. 
Hydrogen peroxide can cross biological membranes. Catalase 
detoxifies hydrogen peroxide which plays the principal role in tissue 
damage. So, the reduction in SOD may damage the first line of 
enzymatic defense against superoxide anion and hydrogen peroxide. 
The significant depletion in GSH in liver of diabetic rats indicates 
damage to the second line of antioxidant defense [37].  
This probably further exacerbates oxidative damage by adversely 
affecting critical GSH related processes such as free radical 
scavenging, detoxification of electrophilic compounds, modulation of 
cellular redox status and thiol disulphide status of proteins, and 
regulation of cell signaling and repair pathways [38]. 
Significant increase in inflammatory markers; CRP and TNF-α was 
noticed in diabetic rats however, IL-10 showed the significant 
decrease. Type II diabetes mellitus (T2DM) is considered as a 
metabolic pro-inflammatory disorder that has severe hyperglycemia 
and highly levels of circulating cytokines [39]. CRP is a sensitive 
marker of systemic inflammation and is conjugated with type 2 
diabetic [40]. It is observed that, CRP levels were highly increased in 
case of diabetic rats. This is may be due to the dysfunction of β-cell 
in insulin resistance [41]. In agreement with the present results, 
Habib [42] reported that diabetic patients have higher levels of CRP 
than healthy ones.  
Regarding to TNF-α, an adipocytokine, is involved in inflammation 
[43]. In the present study, TNF-α level is highly increased in diabetic 
rats. In concern with the present results, elevated levels of TNF-α 
associated with diabetes [44]. With respect to IL-10 cytokines, is 
identified as an important modulator of inflammatory cytokines 
production [45]. The current results are in accordance with Van Exel 
et al. [46] who revealed IL-10 levels decreased in type 2 diabetic 
patients. Also, high concentrations of glucose lead to high production 
of intracellular reactive oxygen species (ROS) [47] consequently, 
ROS production can lead to high production of pro-inflammatory 
cytokines that can affect β-cells in a paracrine manner [48]. 
With respect to cholinergic markers, the present results show the 
significant increase in brain activity of AchE with concomitant 
decrease in Ach level in STZ induced diabetic rats. Kaizer et al. [49] 
suggested that the increased in AchE activity was occurred via 
allosteric interaction between ROS and the peripheral anionicsite of 
the enzyme molecule, free radical action has been shown to increase 
in brain of diabetic rats, It is known that certain regions of the brain 
are very rich in iron, and is catalytically involved in production of 
damaging oxygen free radical species [50]. 
Our results show that in hyperglycemic rats, the AchE activity was 
significantly decreased. Streptozotocin (STZ), when injected 
intraperitoneal in a single dose to rats, has been found to cause 
prolonged impairment of brain glucose and energy metabolism. This 
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is accompanied by impairment of learning and memory in addition 
to decrease cholineacetyl transferase levels in the hippocampus [51]. 
The changes in the cholinesterase level might reflect impairment in 
biosynthesis, degradation or insertion into the plasma membrane 
[52]. The decreased AChE activity by the lipid peroxid ation was 
reversed when diabetic rats were treated with vitamin E and 
coenzyme Q10. The observed stimulation of AChE activity in diabetic 
rats treated may possibly be due to increase in membrane fluidity. It 
has been suggested that coenzyme Q10 and vitamin E with 
Glibenclamide acts directly on cholinesterase, therefore, they seem 
to protect the enzyme against the direct actions of free radicals. This 
action could be exerted on cysteine, methionine, and histidine 
and/or tyrosine residue to the AChE and BChE molecule [53]. Taken 
together, our data suggested that coenzyme Q10 and vitamin E 
increase AChE activity by increasing membrane fluidity and 
decreasing lipid peroxidation.  
The above observation indicates that it may be possible to ambient 
cholinergic function by inhibiting Streptozotocin-induced decrease 
in cholinergic neuraldys function during diabetes through increasing 
antioxidant. In parallel results, vitamin E is a powerful antioxidant 
that has been shown to decrease several outcomes of oxidative 
stress and oxidative damage in cell culture, in animal models of 
diabetes, and in diabetic humans. Because vitamin E is located in 
membranes and serves to reduce lipid peroxidation primarily as a 
chain-breaking antioxidant. Vitamin E given to diabetic animals has 
been shown to exhibit effects in several tissues as well, including 
kidney retina and lens, peripheral nerve, brain, and liver [54]. 
Minamiyama et al. [55] declared that antioxidant interventions have 
been shown to decrease oxidized protein levels in rats. Vitamin E 
reduces protein oxidation, lowered protein carbonyl content in the 
livers and brain mitochondria of Streptozotocin-induced diabetic 
rats. Vitamin E has been shown to inhibit the glycation of 
hemoglobin, which serves as a biomarker for the diagnosis of 
diabetes in a clinical setting, in both Streptozotocin-induced diabetic 
rats and in a rat model for type 2 diabetes. The mechanism by which 
vitamin E lowers protein glycation has been shown to be through 
inhibition of MDA formation, which contributes to the glycation of 
proteins in diabetics. Therefore, evidence does support an increase in 
both protein oxidation and glycation in diabetes and a suppressive effect 
of vitamin E on these parameters, in animal model [55]. 
Pazdro and Burgess [54] reported that GPx, GSH, and vitamin E are 
all lower in the kidney and lens of diabetic rats when compared to 
non-diabetic controls and that these effects may be improved with 
exercise and supplementation with vitamins C and E. Thus, 
treatment with insulin or antioxidants appeared to normalize an 
antioxidant defense system. In accordance with the present results 
Takatori et al.[56], indicated a role for oxidative stress in 
development of Streptozotocin-induced diabetes, as antioxidants 
have been found to slow or prevent pancreatic complications after 
administration of this agent So, vitamin E improves outcomes 
related to pancreas physiology in diabetes. 
Pazdro and Burgess [54] found that rats deficient in vitamin E, 
selenium, or both had decreased insulin secretory reserves, 
suggesting that vitamin E status can directly affect pancreatic islet 
function. Supplementation with vitamin E appeared to lower plasma 
glucose in type 2 diabetic humans. However, Koya et al. [57] have 
shown vitamin E supplementation to reduce oxidative stress in 
glomeruli of diabetic rats. Oxidative stress in diabetic kidney is 
usually associated with tissue damage that interferes with proper 
organ function, causing an increase in urinary protein excretion and 
blood urea nitrogen (BUN). Vitamin E supplementation (1000 IU/kg 
diet) for 4 w. after Streptozotocin-induction of diabetes resulted in 
significant reductions in both measures as compared to diabetic rats 
on a control diet.  
Moreover, Haidara et al. [58] are supporting our data by confirming 
the effect of vitamin E in reducing BUN and serum creatinine in 
diabetic rats, demonstrating a positive effect on kidney function. 
With respect to the treatment o diabetic rats with coenzyme Q10, it 
primary role of CoQ10 is as a vital intermediate of the electron 
transport system in the mitochondria. Adequate amounts of 
coenzyme Q10 are necessary for cellular respiration and ATP 
production. Due to its involvement in ATP synthesis, coenzyme Q10 
affects the function of all cells in the body, making it essential for the 
health of all tissues and organs. CoQ10 also functions as an 
intercellular antioxidant at the mitochondrial level, perhaps 
accounting for its benefit in neurodegenerative diseases, male 
infertility, and periodontal disease [59]. 
The electron-transport chain is integrally involved in carbohydrate 
metabolism. Serum CoQ10 levels in type 2 diabetic patients are often 
decreased and may be associated with subclinical diabetic 
cardiomyopathy, reversible by coenzyme Q10 supplementation. Its 
supplementation may be raised plasma coenzyme Q10 levels, and in 
combination with fenofibrate markedly improved both endothelial 
and non-endothelial forearm vasodilatations. [60, 61]. In addition, 
coenzyme Q10 has attracted increasing attention with regard to its 
function in the reduced form (ubiquinol-10) as an antioxidant. 
Ubiquinol-10 efficiently protects membrane phospholipids and 
serum low-density lipoprotein from lipid peroxidation and also 
mitochondrial membrane proteins and DNA from oxidative damage 
induced by free radicals. Ubiquinol-10 is as effective in preventing 
oxidative damage to lipids as alpha-tocopherol, and is considered to 
be the best lipid-soluble antioxidant [62]. 
Coenzyme Q10 by electron transport carriers present in various 
biomembranes and by some enzymes and to protect membrane 
components from free radical damage such as lipid peroxidation 
[63]. In various studies, it has been reported that diabetes developed 
by STZ causes histological changes in liver and kidney [28]. 
In our study, nuclear hypertrophy and binuclear hepatocytes, 
hyperplastic glomeruli, necrotic degeneration of Purkinje neurons 
were observed in liver, kidney and brain tissues of diabetic control 
groups, whereas normal formations were seen in liver histology of 
control groups and treated diabetic group. As a result, we observed 
that the CO10 and Vit E shows ant diabetic and antioxidative 
properties in diabetes complications, and glibenclamide cured 
partially the defects of antioxidant enzymes and histological 
structure caused by diabetes by reducing blood sugar. Hence, there 
is need for conducting clinical research in supplementation CO10 
and Vit. E. Glibenclamide alone or with CO10 and Vit E treated 
diabetic group. Hepatocytes and sinusoidal structures in diabetic-or 
with CO10 and Vit E group showed nearly normal histology 
CONCLUSION 
It has been demonstrated that diabetes induces oxidative stress and 
the resulting damage may be mitigated by treatment with vitamin E 
and CO10 as antioxidant. Vitamin E exerts effects based primarily on 
residing cell membranes and lipoprotein particles, vitamin E 
appears to protect against macromolecule damage especially lipid 
peroxidation–in STZ experimental diabetes. The present results are 
also evidenced to support a role of vitamin E and CO10 in protection 
of the liver, kidney, and brain against the development of diabetic 
complications in animals. Vitamin E and CO10 may protect against 
lipid peroxidation and to a lesser extent nitric oxide in diabetic rats. 
Optimizing vitamin E and CO10 status achieved through food intake 
or supplementation at the recommended amounts may slow the 
progression of the tissue damage in diabetes, but more studies are 
needed before definitive conclusions can be drawn. 
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